Suppl. Fig. 1 Characterization for pSTAT3 activation in cancer cell lines responding to Debio 0617B in vitro by Western blot analysis.Suppl. Fig. 2 A-C. Efficacy studies with Debio 0617B in A549, A2058 and A431 models: body weight loss/gain (%). Suppl. Fig. 3A. Histopathology of primary tumors in the 4T1 mammary tumor model. 3B. Efficacy of Debio 0617B in the 4T1 neoadjuvant mammary tumor model: body weight loss/gain (%).